Neurology 2014-05-06

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Peter A Lewitt, M Maral Mouradian

Index: Neurology 82(18) , 1574-5, (2014)

Full Text: HTML

Abstract

After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements. Whether disabling or minor, levodopa-induced dyskinesia (LID) constitutes an undesirable outcome calling for better treatment strategies. Options for managing LID include delaying its onset by combining a dopaminergic agonist with levodopa from the start(1) or symptomatic control using amantadine. However, fundamental questions about LID remain: by what mechanisms does it develop, and why don't all patients go on to experience LID after sustained levodopa exposure?

Related Compounds

Structure Name/CAS No. Articles
2-Deoxy-2-fluoro-D-glucose Structure 2-Deoxy-2-fluoro-D-glucose
CAS:29702-43-0
Adamantan-1-amine Structure Adamantan-1-amine
CAS:768-94-5
1-Adamantanamine hydrochloride Structure 1-Adamantanamine hydrochloride
CAS:665-66-7